The cerebroprotective effects of pentoxifylline and aprotinin during cardiopulmonary bypass in dogs

Abstract

Objective: The purpose of this study was to investigate the cerebroprotective effects of pentoxifylline (PNX) and aprotinin in dogs using cardiopulmonary bypass (CPB).

Materials and methods: Eighteen clinically healthy dogs were divided into three groups: Group 1 (control, n = 6), Group 2 (PNX, n = 6), and Group 3 (aprotinin, n = 6). PNX was administered at a dose of 300 mg/day in Group 2 three days before the operation and during the operation. Half a million IU aprotinin were added to the prime solution and 500 000 IU were transfused via a central venous jugular catheter preoperatively in Group 3. Blood samples were taken from the central jugular vein before and after CPB and interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and S100β protein were measured. Gliosis was investigated histopathologically in cerebral cortex biopsy samples under light microscopy.

Results: The preoperative results of IL-6, TNF-α, and S100β protein values were found to be significantly higher (p < 0.001) when compared with postoperative values. This significant difference was observed in the same parameters between Groups 1 and 2, and 1 and 3 (p < 0.001). There was no significant difference between Groups 2 and 3. Comparison between pre- and postoperative levels of IL-6 and TNF-α for Group 2 and Group 3 revealed statistically significant differences (p < 0.001), whereas S100β protein levels did not. Histopathological examinations showed significant differences between the control group and PNX and aprotinin, and between aprotinin and PNX groups (p < 0.001).

Conclusion: PNX and aprotinin might be useful in order to reduce postoperative cerebral damage in patients undergoing cardiac surgery with CPB.

Get full access to this article

View all access options for this article.

References

Dennis C , Spreng DS Jr , Nelson GE. Development of a pump-oxygenator to replace the heart and lungs; an apparatus applicable to human patients and application to one case . Ann Surg 1951; 134: 709-721 .

Roach GW , Kanchuger M , Mangano CM et al. Adverse cerebral outcomes after coronary bypass surgery . N Engl J Med 1996; 35: 1857-1863 .

Horton SB , Butt WW , Mullaly RJ et al. IL-6 and IL-8 levels after cardiopulmonary bypass are not affected by surface coating . Ann Thorac Surg 1999; 68: 1751-1755 .

Jensen E , Sandström K , Andreasson S , Nilsson K , Berggren H , Larsson LE. Increased levels of S-100 protein after cardiac surgery with cardiopulmonary bypass and general surgery in children . Paed Anaesth 2000; 10: 297-302 .

Ali MS , Harmer M , Vaughan RS , Dunne J , Latto IP. Early release pattern of S-100 protein as a marker of brain damage after warm cardiopulmonary bypass . Anaesthesia 2000; 55: 798-810 .

Westaby S. Aprotinin in perspective . Ann Thorac Surg 1993; 55: 1033-1041 .

Nagahiro I , White T , Yano M et al. Recombinant kunitz protease inhibitor ameliorates reperfusion injury in rat lung transplantation . Ann Thorac Surg 1998; 66: 351-355 .

Bessler H , Gilgal R , Djaldetti M , Zahavi I. Effect of pentoxifylline on the phagocytic activity cAMP levels and superoxide anion production by monocytes and polymorphonuclear cells . J Leukoc Biol 1986; 40: 747-754 .

Guide for the care and use of laboratory animals. Health and Human Services, Washington DC : NIH publication 86-23, 1985.

10.

Smith PLC. The systemic inflammatory response to cardiopulmonary bypass and the brain . Perfusion 1996; 11: 196-199 .

11.

Kirklin JK , Westaby S , Blackstone EH , Kirklin JW , Chenoweth DE , Pacifico AD. Complement and damaging effects of cardiopulmonary bypass . J Thorac Cardiovasc Surg 1983; 86: 845-857 .

12.

Frering B , Philip M , Dehoux C , Rolland JM , Langlois, Desmonts JM. Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass . J Thorac Cardiovasc Surg 1994; 108: 636-641 .

13.

Roth-Isigkeit A , Schwarzenberger J , Borstel TV et al. Perioperative cytokine release during coronary artery bypass grafting in patients of different ages . Clin Exp Immunol 1998; 114: 26-32 .

14.

Ashraf SS , Tian Y , Zacharrias S , Cowan D , Martin P , Watterson K. Effects of cardiopulmonary bypass on neonatal and pediatric inflammatory profiles . Eur J Cardiothorac Surg 1997; 12: 862-868 .

15.

Dehoux M , Philip I , Chollet-Martin S et al. Early protection of interleukin-10 during normothermic cardiopulmonary bypass . J Thorac Cardiovasc Surg 1995; 110: 286-287 .

16.

Westaby S , Johansson P , Parry AJ et al. Serum S-100 protein: a potential marker for cerebral events during cardiopulmonary bypass . Ann Thorac Surg 1996; 61: 88-92 .

17.

Raabe A , Menon DK , Gupta S , Czosnyka M , Pickard JD. Jugular venous and arterial concentrations of serum S100b protein in patients with severe head injury: a pilot study . J Neurol Neurosurg Psychiatry 1998; 65: 930-932 .

18.

Hermann M , Ebert AD , Galazky I , Wunderlich MT , Kunz WS , Huth C. Neurobehavioral outcome prediction after cardiac surgery: role of neurobiochemical markers of damage to neuronal and glial brain tissue . Stroke 2000; 31: 645-650 .

19.

Jönsson H. S100b as a diagnostic tool for brain damage after cardiac surgery. In Baykut D , Krian A eds. Current perspectives of the extracorporeal circulation, New-York, NY: Springer , 2000: 91-101.

20.

Özatik MA , Tarcan O , Kale A et al.

Do S100b protein level increases due to inflammation during cardiopulmonary bypass occur without any neurological deficit?

Perfusion 2002; 17: 335-338 .